Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

What to Expect From Celgene Corporation in 2018

TheMotleyFool

0 0

What to Expect From Celgene Corporation in 2018

After two years of lackluster performances, Celgene Corporation (NASDAQ: CELG) appeared to be on a roll in 2017. Then the bottom fell out.

In October, the big biotech stock gave up all of its year-to-date gains, and then some. A massive sell-off resulted from the late-stage clinical failure for GED-0301, and third-quarter headwinds for Otezla. What was once a promising year turned into another disappointment for Celgene shareholders.

Will Celgene have better luck next year? Here's what to expect from the biotech in 2018.

Source: Fool.com